…scientific team [claims it] sees tremendous opportunities for both composition of matter as well as process innovations in the psychedelic arena, and we will simultaneously pursue these opportunities to expand Mindset’s IP library.

Mindset CEO James Lanthier commented: “Synthesizing patentable, next-generation compounds is a critical step in our pre-clinical work as we make progress towards identifying a lead compound for later-stage testing and clinical trials and maintaining our first-to-file advantage.”

Original Article (Yahoo):
Mindset pharma synthesizes second generation medicinal psychedelic compounds
Artwork Fair Use: BaharArin